# US 2021/0311034 A1 · Sensor for liquid biopsy and its method of making, and method of non-invasive liquid biopsy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0311034 A1
- Document ID: US20210311034A1
- Status: Published application
- Kind: A1
- Application number: 16/839,158
- Filed: 2020-04-03
- Published: 2021-10-07
- Earliest claimed: 2020-04-03
- Assignees: City University of Hong Kong
- Applicants: City University of Hong Kong
- Inventors: Youngjin Lee; Abhimanyu Thakur; Chi-Man Lawrence Wu; Chen Xu; Siu-Pang Ng
- Web page: https://patentgrep.com/patent/US20210311034A1

## CPC

- G01N 33/543: with an insoluble carrier for immobilising immunochemicals
- G01N 33/54373: {involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings}
- A61B 10/0045: {Devices for taking samples of body liquids}
- A61B 10/02: Instruments for taking cell samples or for biopsy {(A61B10/0038 and A61B10/0045 take precedence; needle locating or guiding means A61B17/3403; samplers for enzymology or microbiology C12M1/26; sampling or preparing biological specimens G01N33/48)}
- B01L 3/502: {with fluid transport, e.g. in multi-compartment structures}
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2884: {against CD44}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- G01N 33/5076: {involving cell organelles, e.g. Golgi complex, endoplasmic reticulum}
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G01N 33/57585: {involving compounds identifiable in body fluids}
- B01L 2300/0636: Integrated biosensor, microarrays
- B01L 2300/0803: Disc shape
- B01L 2300/0861: Configuration of multiple channels and/or chambers in a single devices
- B01L 2300/12: Specific details about materials
- B01L 2400/0484: Cantilevers
- G01N 2333/70585: CD44
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2333/71: for growth factors; for growth regulators
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A sensor for liquid biopsy, its method of making, and its method of non-invasive use. The sensor includes a substrate with a surface functionalized with biotinylated antibodies. The biotinylated antibodies are arranged to engage with surface proteins on exosomes associated with malignant cancer cells such as glioma cells.

## Claims

### Claim 1

A sensor for liquid biopsy, comprising:
a substrate with a surface functionalized with biotinylated antibodies, the biotinylated antibodies being arranged to engage with surface proteins on exosomes associated with malignant cancer cells.

### Claim 2 (depends on 1)

The sensor of claim 1, wherein the exosomes are released by the malignant cancer cells.

### Claim 3 (depends on 2)

The sensor of claim 2, wherein the malignant cancer cells are glioma cells.

### Claim 4 (depends on 1)

The sensor of claim 1, wherein the biotinylated antibodies include biotinylated anti-CD63 antibodies.

### Claim 5 (depends on 1)

The sensor of claim 1, wherein the biotinylated antibodies include biotinylated anti-CD44 antibodies.

### Claim 6 (depends on 1)

The sensor of claim 1, wherein the biotinylated antibodies include biotinylated anti-EGFRvIII antibodies.

### Claim 7 (depends on 1)

The sensor of claim 1, wherein the biotinylated antibodies include one or more of: biotinylated anti-CD63 antibodies, biotinylated anti-CD44 antibodies, and biotinylated anti-EGFRvIII antibodies.

### Claim 8 (depends on 1)

The sensor of claim 1, wherein the substrate and the surface are made of the same material.

### Claim 9 (depends on 1)

The sensor of claim 1, wherein the substrate and the surface are made of different materials.

### Claim 10 (depends on 1)

The sensor of claim 1, wherein the surface is made of plasmonic material.

### Claim 11 (depends on 10)

The sensor of claim 10, wherein the plasmonic material comprises titanium nitride or titanium nitride-based material.

### Claim 12 (depends on 1)

The sensor of claim 1, wherein the substrate is in the form of a nanofilm of titanium nitride or titanium nitride-based material.

### Claim 13 (depends on 1)

The sensor of claim 1, wherein the surface is in the form of a nanofilm of titanium nitride or titanium nitride-based material.

### Claim 14 (depends on 13)

The sensor of claim 13, wherein the surface comprises nano-holes.

### Claim 15 (depends on 1)

The sensor of claim 1, wherein the substrate is in the form of a chip or a disc.

### Claim 16 (depends on 1)

The sensor of claim 1, further comprising:
a housing defining a space, the substrate being arranged in the space;
an inlet; and
an outlet;
wherein the inlet, the outlet, and the space are in liquid communication with each other.

### Claim 17 (depends on 1)

The sensor of claim 1, further comprising:
a cantilever for atomic force microscopy, the cantilever being arranged to be operably cooperating with the substrate, the cantilever including a tip with a tip surface functionalized with biotinylated antibodies complementary to surface proteins on the exosomes.

### Claim 18 (depends on 17)

The sensor of claim 17, wherein the biotinylated antibodies on the tip surface include biotinylated anti-CD44 antibodies.

### Claim 19 (depends on 1)

The sensor of claim 1, further comprising:
a cantilever for atomic force microscopy, the cantilever being arranged to be operably cooperating with the substrate, the cantilever including a tip with a tip surface functionalized with biotinylated hyaluronic acid complementary to surface proteins on the exosomes.

### Claim 20

A method of non-invasive liquid biopsy, comprising
providing a solution containing exosomes associated with malignant cancer cells to a substrate with a surface functionalized with biotinylated antibodies, the biotinylated antibodies being arranged to engage with surface proteins on the exosomes associated with malignant cancer cells; and
detecting exosomes engaged with the surface of the substrate.

### Claim 21 (depends on 20)

The method of claim 20, further comprising:
determining a severity of the malignant cancer based on the detection.

### Claim 22 (depends on 20)

The method of claim 20, further comprising:
performing localized surface plasmon resonance spectroscopy using the substrate engaged with the exosomes.

### Claim 23 (depends on 20)

The method of claim 20, further comprising:
performing atomic force microscopy using the substrate engaged with the exosomes.

### Claim 24 (depends on 20)

The method of claim 20, wherein the exosomes are released by the malignant cancer cells.

### Claim 25 (depends on 24)

The method of claim 24, wherein the malignant cancer cells are glioma cells.

### Claim 26 (depends on 20)

The method of claim 20, wherein the biotinylated antibodies include one or more of: biotinylated anti-CD63 antibodies, biotinylated anti-CD44 antibodies, and biotinylated anti-EGFRvIII antibodies.

### Claim 27

A method for making a sensor for liquid biopsy, the method comprising
providing a substrate with a surface; and
functionalizing the surface with biotinylated antibodies, the biotinylated antibodies being arranged to engage with surface proteins on exosomes associated with malignant cancer cells.

### Claim 28 (depends on 27)

The method of claim 27, wherein the exosomes are released by the malignant cancer cells.

### Claim 29 (depends on 28)

The method of claim 28, wherein the malignant cancer cells are glioma cells.

### Claim 30 (depends on 27)

The method of claim 27, wherein the biotinylated antibodies include one or more of: biotinylated anti-CD63 antibodies, biotinylated anti-CD44 antibodies, and biotinylated anti-EGFRvIII antibodies.

### Claim 31 (depends on 27)

The method of claim 27, wherein the surface is made of plasmonic material.

### Claim 32 (depends on 31)

The method of claim 31, wherein the plasmonic material comprises titanium nitride or titanium nitride-based material.

### Claim 33 (depends on 31)

The method of claim 31, wherein the surface comprises nano-holes.

### Claim 34 (depends on 27)

The method of claim 27, further comprising:
forming the substrate with the surface.

### Claim 35 (depends on 34)

The method of claim 34, wherein forming the substrate comprises:
depositing a film made of gold on a glass substrate;
annealing the glass substrate with deposited gold film such that the gold film at least partly becomes gold nano-islands that are at least partly received in the glass substrate;
deposit a firm of titanium nitride or titanium nitride-based material on the annealed glass substrate with gold nano-islands; and
removing the gold nano-islands.

### Claim 36 (depends on 35)

The method of claim 35, wherein the annealing is performed for around 9 hours at 500 to 600 degree-Celsius.

### Claim 37 (depends on 35)

The method of claim 35, wherein the removal of the gold nano-islands is by immersion to a gold-dissolved solution.
